Samoan
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Vaega o oloa
Oloa Fa'apitoa
Lenopril Tablets e fa'amalosia ai le fa'atonutonuina o le toto ma le soifua maloloina o le fatu

Lenopril Tablets e fa'amalosia ai le fa'atonutonuina o le toto ma le soifua maloloina o le fatu
Telmisartan Sili atu fa'ama'i maualuga Puipuiga o fatu

Telmisartan Sili atu fa'ama'i maualuga Puipuiga o fatu
Flumazenil O se GABAA Receptor Antagonist Filifili ma ana Fa'atonuga Fa'afoma'i

Flumazenil O se GABAA Receptor Antagonist Filifili ma ana Fa'atonuga Fa'afoma'i
Trametinib Kinase Inhibitor e fa'atatau i le BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor e fa'atatau i le BRAF V600 Mutation-Positive Cancers
Dabrafenib Ose Togafitiga Fa'atatau ile BRAF-Mutated Cancers

Dabrafenib Ose Togafitiga Fa'atatau ile BRAF-Mutated Cancers
Tirzepatide Dual GLP-1 ma le GIP Receptor Agonist mo le puleaina o le mamafa ma le puleaina o le Glycemic.

Tirzepatide Dual GLP-1 ma le GIP Receptor Agonist mo le puleaina o le mamafa ma le puleaina o le Glycemic.
Cisapride Gastric Stimulant mo le Ga'i'ai ma Fa'afitauli Fa'aliga

Cisapride Gastric Stimulant mo le Ga'i Gauai ma Fa'afitauli Fa'aliga
YK-11 SARM Malosi mo le Fausiaina o Musole, Malosiga Faʻateleina, ma le Myostatin Inhibition

YK-11 SARM Malosi mo le Fausiaina o Musole, Malosiaga Maua, ma le Myostatin Inhibition
Ostarine (MK-2866) SARM Tele mo le Tuputupu aʻe o Musole, Gaʻo Gaʻo, ma le Toe Faʻafouina o le Tino.

Ostarine (MK-2866) SARM Tele mo le Tuputupu aʻe o Musole, Gaʻo Gaʻo, ma le Toe Faʻafouina o le Tino.
MK-677 Tulaga Tulaga mo Musole Tuputupu, Tumau, ma Toe Fa'aleleia

MK-677 Tulaga Tulaga mo Musole Tuputupu, Tumau, ma Toe Fa'aleleia
0102030405
Trametinib Kinase Inhibitor e fa'atatau i le BRAF V600 Mutation-Positive Cancers
Trametinib Kinase Inhibitor e fa'atatau i le BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor e fa'atatau i le BRAF V600 Mutation-Positive Cancers

Tau faʻamatalaga: USD 8-15 / g

  • Igoa Oloa Trametinib
  • CAS Nu. 871700-17-3
  • MF C26H23FIN5O4
  • MW 615.402623
  • Malosi 1.743
  • Liu liusuavai 293-303°C
Faafesootai matou
fa'amatalaga o oloa

Fa'amatalaga Auiliili

O le Trametinib o se iniseti kinase malosi ma filifilia e masani ona faʻaaogaina i le togafitiga o le melanoma e le mafai ona faʻaaogaina poʻo le metastatic ma le BRAF V600 mutation, faʻapea foʻi ma ituaiga faʻapitoa o le kanesa o le mama sela e le o ni metastatic. O lenei tusiga o loʻo suʻesuʻeina le faiga o gaioiga, faʻamatalaga faʻapitoa, ma faʻamanuiaga o le trametinib i le togafitiga o BRAF V600 mutation-positive cancers.

I. Malamalama i Trametinib:
A. Oral, malosi, ma filifili kinase inhibitor
B. E auai i le vasega inhibitors MEK
C. poloka le gaioiga kinase o MEK1 ma MEK2
D. Faʻasaʻo lalo ifo ERK1 ma ERK2 faailoilo

II. Fa'ailoga Fa'afoma'i:
A. Melanoma e le mafai ona toe fa'asa'o pe fa'ama'i pipisi o lo'o iai suiga ole BRAF V600:
Togafitiga tu'ufa'atasi ma le dabrafenib mesylate
B. Togafitiga fa'aopoopo pe a mae'a le taotoga mo le BRAF V600 mutation-positive melanoma:
Togafitiga fa'atasi ma le dabrafenib mesylate pe a mae'a fa'amama

17161152266097be

III. Matafaioi i le kanesa o le mama e le o ni sela laiti:

A. O le kanesa o le mama e le o ni sela laiti e avea ma mafua'aga autu o le ma'i ma le oti

B. BRAF fua fa'aliliuga kenera ma fa'ateleina ole suiga ole BRAF V600E

C. A'afiaga fa'alavelave a Trametinib ile BRAF V600 mutation-positive melanoma sela


IV. Mechanism of Action:

A. Fa'alavelave toe fa'afo'i o le mitogen-activated extracellular signal-regulated kinase (MEK) 1 ma MEK2

B. A'afiaga ile ala MAPK ma le polotini MEK

C. Fa'asaina o le fa'atuputeleina o le sela ma lalo ole ala ERK


V. Togafitiga Fa'aopoopo Fa'auma ole taotoga:

A. Fa'amanuiaga o togafitiga fa'atasi fa'atatau ma Dabrafenib ma Trametinib

B. Fa'amanuiaga mo se taimi umi, tumau e aunoa ma le toe fa'afo'isia (RFS) i tulaga lamatia maualuga III BRAF mutation-lelei melanoma ma'i.



O le Trametinib, o le iniseti o le kinase, o loʻo faʻaalia ai le aoga tele i le togafitiga o BRAF V600 mutation-positive cancers, aemaise le melanoma e le mafai ona faʻaaogaina pe metastatic ma ituaiga faʻapitoa o le kanesa o le mama sela laiti. O lona faʻaogaina o gaioiga, faʻalavelaveina MEK1 ma MEK2 kinase gaioiga, e taʻitaʻia ai i lalo ole ala ERK ala faʻafefe ma taofiofia le faʻateleina o le cell. Trametinib, faʻatasi ma le dabrafenib mesylate, e maua ai faʻamanuiaga faʻapitoa i tulaga faʻapitoa ma faʻapipiʻi mo BRAF V600 mutation-positive melanoma maʻi.
Fa'afeso'ota'i matou mo fautuaga mo vaila'au ma fa'amatalaga tau fa'atausi'i atoa e fa'aleleia ai le tausiga o ma'i.

Fa'amatalaga

171611254334271z